{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:20:03Z","timestamp":1780492803168,"version":"3.54.1"},"reference-count":114,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Marginal zone lymphomas (MZLs) are a rare, indolent group of non\u2010Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa\u2010associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing\/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence\u2010based recommendations in the setting of Australia and New Zealand.<\/jats:p>","DOI":"10.1111\/imj.16390","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T09:01:31Z","timestamp":1718614891000},"page":"1017-1030","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-4003","authenticated-orcid":false,"given":"Masa","family":"Lasica","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology St Vincent's Hospital  Melbourne Victoria Australia"},{"name":"The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Royal Melbourne Hospital and The Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Division of Blood Cells and Blood Cancer Walter and Eliza Hall Institute  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Boussioutas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Alfred Health  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"},{"name":"The Alfred  Melbourne Victoria Australia"},{"name":"Familial Cancer Clinic Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-0682","authenticated-orcid":false,"given":"Gareth P.","family":"Gregory","sequence":"additional","affiliation":[{"name":"Clinical Sciences at Monash Health Monash University  Melbourne Victoria Australia"},{"name":"Monash Haematology, Monash Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-1450","authenticated-orcid":false,"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Manos","sequence":"additional","affiliation":[{"name":"Department of Haematology Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"McKelvie","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology St Vincent's Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ng","sequence":"additional","affiliation":[{"name":"GenesisCare St Vincent's Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Clinical Pathology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Palfreyman","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Darwin Hospital  Darwin Northern Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-5503","authenticated-orcid":false,"given":"Ross","family":"Salvaris","sequence":"additional","affiliation":[{"name":"Department of Haematology Sir Charles Gairdner Hospital  Perth Western Australia Australia"},{"name":"School of Medicine University of Western Australia  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weinkove","sequence":"additional","affiliation":[{"name":"Te Rerenga Ora Blood &amp; Cancer Centre Te Whatu Ora Health New Zealand Capital, Coast &amp; Hutt Valley  Wellington New Zealand"},{"name":"Cancer Immunotherapy Programme Malaghan Institute of Medical Research  Wellington New Zealand"},{"name":"Department of Pathology and Molecular Medicine University of Otago Wellington  Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Wight","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Townsville University Hospital  Townsville Queensland Australia"},{"name":"School of Medicine James Cook University  Townsville Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"Monash Haematology, Monash Health  Melbourne Victoria Australia"},{"name":"School of Clinical Sciences at Monash Health Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"Haematology Department Alfred Hospital  Melbourne Victoria Australia"},{"name":"Central Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001\u20102009 with a focus on primary anatomic site","volume":"165","author":"Khalil MO","year":"2014","journal-title":"Br J Haematol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41375-022-01625-x","article-title":"The WHO classification of haematolymphoid tumours","volume":"36","author":"Cree IA","year":"2022","journal-title":"Leukemia"},{"key":"e_1_2_10_4_1","unstructured":"Unpublished Data. LaRDRL. 2023. Available from URL:https:\/\/lardr.org."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.007"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3324\/haematol.2019.227272","article-title":"MYD88 in the driver's seat of B\u2010cell lymphomagenesis: from molecular mechanisms to clinical implications","volume":"104","author":"Groen RAL","year":"2019","journal-title":"Haematologica"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/PAS.0000000000000411","article-title":"MYD88 (L265P) somatic mutation in marginal zone B\u2010cell lymphoma","volume":"39","author":"Martinez\u2010Lopez A","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071742","article-title":"Extranodal marginal zone lymphoma: pathogenesis, diagnosis and treatment","volume":"14","author":"Di Rocco A","year":"2022","journal-title":"Cancers (Basel)"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-13","article-title":"Present role and future perspective of PET\u2010CT in marginal zone lymphoma","volume":"4","author":"Ceriani L","year":"2020","journal-title":"Ann Lymphoma"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2141.2006.06444.x","article-title":"Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10\u2009years?","volume":"136","author":"Ferrucci PF","year":"2007","journal-title":"Br J Haematol"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/cncr.11415","article-title":"Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends","volume":"97","author":"Nakamura S","year":"2003","journal-title":"Cancer"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdn525","article-title":"Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management","volume":"19","author":"Psyrri A","year":"2008","journal-title":"Ann Oncol"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.07.017"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu H","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","article-title":"EGILS consensus report. Gastric extranodal marginal zone B\u2010cell lymphoma of MALT","volume":"60","author":"Ruskon\u00e9\u2010Fourmestraux A","year":"2011","journal-title":"Gut"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058869"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/gut.52.6.912","article-title":"Paris staging system for primary gastrointestinal lymphomas","volume":"52","author":"Ruskon\u00e9\u2010Fourmestraux A","year":"2003","journal-title":"Gut"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"350","author":"Lecuit M","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri AJ","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj406"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.25122\/jml-2018-0035","article-title":"MALT lymphoma: epidemiology, clinical diagnosis and treatment","volume":"11","author":"Violeta Filip P","year":"2018","journal-title":"J Med Life"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","journal-title":"Leukemia"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/imj.14268","article-title":"Front\u2010line management of indolent non\u2010Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma","volume":"49","author":"Cheah CY","year":"2019","journal-title":"Intern Med J"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.beha.2016.09.005","article-title":"Splenic marginal zone lymphoma","volume":"30","author":"Piris MA","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal\u2010zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont C","year":"2003","journal-title":"Lancet Oncol"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini L","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart J","year":"2014","journal-title":"Thromb Res"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjh.13908","article-title":"High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiency","volume":"172","author":"Castelli R","year":"2016","journal-title":"Br J Haematol"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes E","year":"2008","journal-title":"Leukemia"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3109\/10428194.2015.1106535","article-title":"Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation","volume":"57","author":"Brand M","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: present status and future perspectives","volume":"107","author":"Cheah CY","year":"2022","journal-title":"Haematologica"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi A","year":"2015","journal-title":"Ann Oncol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-8","article-title":"Prognostic factors and risk of transformation in marginal zone lymphoma","volume":"4","author":"Alderuccio JP","year":"2020","journal-title":"Ann Lymphoma"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont C","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1182\/bloodadvances.2022007322","article-title":"A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile","volume":"6","author":"Salmeron\u2010Villalobos J","year":"2022","journal-title":"Blood Adv"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B\u2010cell lymphoma of mucosa\u2010associated lymphoid tissue","volume":"101","author":"Zucca E","year":"2003","journal-title":"Blood"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini L","year":"2004","journal-title":"Cancer"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ajh.26715","article-title":"Revised MALT\u2010IPI: a new predictive model that identifies high\u2010risk patients with extranodal marginal zone lymphoma","volume":"97","author":"Alderuccio JP","year":"2022","journal-title":"Am J Hematol"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher\u2010grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio JP","year":"2018","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.33117","article-title":"Splenic marginal zone lymphoma: a US population\u2010based survival analysis (1999\u20102016)","volume":"126","author":"Florindez JA","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chac\u00f3n JI","year":"2002","journal-title":"Blood"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini L","year":"2006","journal-title":"Blood"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n C","year":"2012","journal-title":"Br J Haematol"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173247","article-title":"Favorable outcomes of splenic marginal zone lymphoma in an international study of 934 patients with long follow\u2010up","volume":"142","author":"Ludvigsen Al\u2010Mashhadi A","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski AJ","year":"2013","journal-title":"Cancer"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_63"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner P","year":"2022","journal-title":"Gut"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.3748\/wjg.v29.i14.2202","article-title":"Effectiveness of Helicobacter pylori eradication in the treatment of early\u2010stage gastric mucosa\u2010associated lymphoid tissue lymphoma: an up\u2010to\u2010date meta\u2010analysis","volume":"29","author":"Lemos FFB","year":"2023","journal-title":"World J Gastroenterol"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2006.00460.x"},{"key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.25447","article-title":"Frontline antibiotic therapy for early\u2010stage Helicobacter pylori\u2010negative gastric MALT lymphoma","volume":"94","author":"Strati P","year":"2019","journal-title":"Am J Hematol"},{"key":"e_1_2_10_54_1","first-page":"609","article-title":"Treatment of low grade gastric mucosa\u2010associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long\u2010term results after sequential histologic and molecular follow\u2010up","volume":"86","author":"Montalban C","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_10_55_1","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2005.02.3903","article-title":"Long\u2010term follow\u2010up of gastric MALT lymphoma after Helicobacter pylori eradication","volume":"23","author":"W\u00fcndisch T","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2015.08.029","article-title":"Exclusive moderate\u2010dose radiotherapy in gastric marginal zone B\u2010cell MALT lymphoma: results of a prospective study with a long term follow\u2010up","volume":"117","author":"Ruskon\u00e9\u2010Fourmestraux A","year":"2015","journal-title":"Radiother Oncol"},{"key":"e_1_2_10_57_1","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/bloodadvances.2020003992","article-title":"Involved\u2010site radiotherapy for Helicobacter pylori\u2010independent gastric MALT lymphoma: 26\u2009years of experience with 178 patients","volume":"5","author":"Yahalom J","year":"2021","journal-title":"Blood Adv"},{"key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ijrobp.2020.11.070","article-title":"A prospective trial of radiation therapy efficacy and toxicity for localized mucosa\u2010associated lymphoid tissue (MALT) lymphoma","volume":"109","author":"Fang P","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_10_59_1","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa\u2010associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang RW","year":"2003","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_60_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2019.02.002","article-title":"Outcomes after reduced\u2010dose intensity modulated radiation therapy for gastric mucosa\u2010associated lymphoid tissue (MALT) lymphoma","volume":"104","author":"Pinnix CC","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_10_61_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom J","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_10_62_1","first-page":"79","article-title":"Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT","volume":"24","author":"Christopherson KM","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"e_1_2_10_63_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/hematology.2020000157","article-title":"How do we sequence therapy for marginal zone lymphomas?","volume":"2020","author":"Broccoli A","year":"2020","journal-title":"Hematology"},{"key":"e_1_2_10_64_1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria\u2010eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial","volume":"98","author":"Ferreri AJ","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_10_65_1","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first\u2010line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri AJ","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_66_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00277-014-2240-8","article-title":"Long\u2010term outcomes of first\u2010line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma","volume":"94","author":"Han JJ","year":"2015","journal-title":"Ann Hematol"},{"key":"e_1_2_10_67_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter B","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_68_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/10428194.2012.717279","article-title":"Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma","volume":"54","author":"Tran KH","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_10_69_1","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long\u2010term outcome in localized extranodal mucosa\u2010associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda JS","year":"2010","journal-title":"Cancer"},{"key":"e_1_2_10_70_1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hed.24717","article-title":"Ultra\u2010low\u2010dose radiotherapy for definitive management of ocular adnexal B\u2010cell lymphoma","volume":"39","author":"Pinnix CC","year":"2017","journal-title":"Head Neck"},{"key":"e_1_2_10_71_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13014-022-02180-6","article-title":"Ultra\u2010low\u2010dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study","volume":"17","author":"Yang X","year":"2022","journal-title":"Radiat Oncol"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.004"},{"key":"e_1_2_10_73_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000502204","article-title":"Mucosa\u2010associated lymphoid tissue lymphoma of the thyroid gland: a systematic review of the literature","volume":"9","author":"Karvounis E","year":"2020","journal-title":"Eur Thyroid J"},{"key":"e_1_2_10_74_1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B\u2010cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini L","year":"2014","journal-title":"Ann Oncol"},{"key":"e_1_2_10_75_1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG\u201019 randomized trial of mucosa\u2010associated lymphoid tissue lymphoma: improved event\u2010free and progression\u2010free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca E","year":"2017","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_76_1","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210012","article-title":"Efficacy of low\u2010dose radiotherapy (2 Gy \u00d7\u20092) in the treatment of marginal zone and mucosa\u2010associated lymphoid tissue lymphomas","volume":"94","author":"Cerrato M","year":"2021","journal-title":"Br J Radiol"},{"key":"e_1_2_10_77_1","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon\u2010free antiviral treatment in B\u2010cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini L","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162965"},{"key":"e_1_2_10_79_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis C","year":"2018","journal-title":"Blood"},{"key":"e_1_2_10_80_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non\u2010follicular indolent B\u2010cell non\u2010Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams ME","year":"2016","journal-title":"Br J Haematol"},{"key":"e_1_2_10_81_1","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long\u2010term follow\u2010up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first\u2010line treatment","volume":"55","author":"Lenglet J","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_10_82_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120547","article-title":"Prediction of technical difficulties in laparoscopic splenectomy and analysis of risk factors for postoperative complications in 468 cases","volume":"7","author":"Wysocki M","year":"2018","journal-title":"J Clin Med"},{"key":"e_1_2_10_83_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijsu.2018.02.042","article-title":"20\u2009years' experience with laparoscopic splenectomy. Single center outcomes of a cohort study of 500 cases","volume":"52","author":"Radkowiak D","year":"2018","journal-title":"Int J Surg"},{"key":"e_1_2_10_84_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1553350611410891","article-title":"Laparoscopic splenectomy: learning curve comparison between benign and malignant disease","volume":"19","author":"Fraser SA","year":"2012","journal-title":"Surg Innov"},{"key":"e_1_2_10_85_1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/imj.13348","article-title":"Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand","volume":"47","author":"Kanhutu K","year":"2017","journal-title":"Intern Med J"},{"key":"e_1_2_10_86_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/imj.15247","article-title":"COVID\u201019 vaccination in haematology patients: an Australian and New Zealand consensus position statement","volume":"51","author":"McCaughan G","year":"2021","journal-title":"Intern Med J"},{"key":"e_1_2_10_87_1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post\u2010hoc efficacy analysis","volume":"19","author":"Dagnew AF","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15641"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-1076-1"},{"key":"e_1_2_10_90_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","article-title":"Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B\u2010R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7\u20102008 MAINTAIN trial)","volume":"36","author":"Rummel MJ","year":"2018","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_91_1","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non\u2010Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30686-0"},{"key":"e_1_2_10_93_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non\u2010Hodgkin lymphoma\u2010target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge T","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_10_94_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First\u2010line treatment of patients with indolent non\u2010Hodgkin lymphoma or mantle\u2010cell lymphoma with bendamustine plus rituximab versus R\u2010CHOP or R\u2010CVP: results of the BRIGHT 5\u2010year follow\u2010up study","volume":"37","author":"Flinn IW","year":"2019","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_10_96_1","article-title":"Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold M","year":"2022","journal-title":"Hema"},{"key":"e_1_2_10_97_1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio JP","year":"2022","journal-title":"Blood Adv"},{"key":"e_1_2_10_98_1","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.22.00668","article-title":"Direct\u2010acting antivirals as primary treatment for hepatitis C virus\u2010associated indolent non\u2010Hodgkin lymphomas: The BArT study of the Fondazione Italiana Linfomi","volume":"40","author":"Merli M","year":"2022","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_99_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.26932","article-title":"Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch\u2010and\u2010wait strategy after complete resection","volume":"65","author":"Ronceray L","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_10_100_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00000478-200304000-00014","article-title":"Marginal zone B\u2010cell lymphoma in children and young adults","volume":"27","author":"Taddesse\u2010Heath L","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"e_1_2_10_101_1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18368"},{"key":"e_1_2_10_104_1","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long\u2010term follow\u2010up and biomarker analysis","volume":"4","author":"Noy A","year":"2020","journal-title":"Blood Adv"},{"key":"e_1_2_10_105_1","doi-asserted-by":"crossref","unstructured":"TatarczuchM WM ShorttJ HawkesE HoSJ TrotmanJ BrasacchioD CoM LiJ RamakrishnanV DunneK OpatS GregoryG.ALLG Laboratory Science Study LS21: Molecular Correlates of Response in Relapse\/Refractory Marginal Zone Lymphoma (RRMZL) Patients treated with Zanubrutinib in the Magnolia Trial EHA; 2022.","DOI":"10.1097\/01.HS9.0000847908.60002.1c"},{"key":"e_1_2_10_106_1","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/bloodadvances.2022009412","article-title":"Molecular associations of response to the new\u2010generation BTK inhibitor zanubrutinib in marginal zone lymphoma","volume":"7","author":"Tatarczuch M","year":"2023","journal-title":"Blood Adv"},{"key":"e_1_2_10_107_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard JP","year":"2019","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_108_1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T\u2010cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non\u2010Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler ME","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_109_1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20\u2010targeting T\u2010cell\u2010engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B\u2010cell lymphoma: a phase I trial","volume":"39","author":"Hutchings M","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_110_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non\u2010Hodgkin lymphoma (ZUMA\u20105): a single\u2010arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson CA","year":"2022","journal-title":"Lancet Oncol"},{"key":"e_1_2_10_111_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma","volume":"5","author":"Panayiotidis P","year":"2021","journal-title":"Blood Adv"},{"key":"e_1_2_10_112_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2078","article-title":"Efficacy of 90Yttrium\u2010ibritumomab tiuxetan in relapsed\/refractory extranodal marginal\u2010zone lymphoma","volume":"32","author":"Vanazzi A","year":"2014","journal-title":"Hematol Oncol"},{"key":"e_1_2_10_113_1","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long\u2010term follow\u2010up of patients with relapsed or refractory non\u2010Hodgkin lymphoma treated with Venetoclax in a phase I, first\u2010in\u2010human study","volume":"27","author":"Davids MS","year":"2021","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_114_1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15454","article-title":"High\u2010dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL\u2010GITMO","volume":"182","author":"Avivi I","year":"2018","journal-title":"Br J Haematol"},{"key":"e_1_2_10_115_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab\u2010based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski AJ","year":"2014","journal-title":"Ann Hematol"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T09:03:23Z","timestamp":1718615003000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/imj.16390"],"URL":"https:\/\/doi.org\/10.1111\/imj.16390","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2023-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}